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Iron plays a fundamental role in the development of the central nervous system (CNS) as
well as in several neuronal functions including synaptic plasticity. Accordingly, neuronal
iron supply is tightly controlled: it depends not only on transferrin-bound iron but also
on non-transferrin-bound iron (NTBI), which represents a relevant quote of the iron
physiologically present in the cerebrospinal fluid (CSF). Different calcium permeable
channels as well as the divalent metal transporter 1 (DMT1) have been proposed to
sustain NTBI entry in neurons and astrocytes even though it remains an open issue. In
both cases, it emerges that the control of iron entry is tightly linked to synaptic activity.
The iron-induced oxidative tone can, in physiological conditions, positively influence the
calcium levels and thus the synaptic plasticity. On the other hand, an excess of iron, with
the ensuing uncontrolled production of reactive oxygen species (ROS), is detrimental
for neuronal survival. A protective mechanism can be played by astrocytes that, more
resistant to oxidative stress, can uptake iron, thereby buffering its concentration in
the synaptic environment. This competence is potentiated when astrocytes undergo
activation during neuroinflammation and neurodegenerative processes. In this minireview
we focus on the mechanisms responsible for NTBI entry in neurons and astrocytes and
on how they can be modulated during synaptic activity. Finally, we speculate on the
relevance they may have in both physiological and pathological conditions.
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Introduction
Iron transport in cells and body fluids requires the participation of specific proteins and
buffering molecules to avoid precipitation of the metal ion, with the potential induction of
cytotoxic effects. In the plasma, the main binding protein is transferrin (Tf), even though heme
and ferritin can contribute to bind and circulate iron. In particular, iron can be transported
as hemoglobin bound to haptoglobin as well as heme directly bound to hemopexin. On the
other hand, ferritin iron represents only a minute amount of the circulating iron (Crichton
and Charloteaux-Wauters, 1987; Brissot et al., 2012). Plasma iron concentration can exceed
the total binding capacity of Tf only in conditions of severe pathological iron overload, as it
occurs, for instance, in different forms of hemochromatosis (Janssen and Swinkels, 2009). Along
with the transferrin-bound iron, another iron pool was identified by Hershko et al. (1978)
and called non-transferrin-bound iron (NTBI). However this definition is somewhat confusing
since NTBI does not include all forms of iron unbound to transferrin; for instance heme and
ferritin iron are excluded (Brissot et al., 2012). Plasmatic NTBI is composed mainly by Fe(III),
loosely bound to buffering molecules (mainly citrate and acetate), but also to the abundant plasma
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protein, albumin (Hider, 2002; Brissot et al., 2012). This pool has
attracted great interest since it may represent a relevant source
of iron for various cell types (e.g., in hepatocytes; Wang and
Knutson, 2013) and can have a pathological relevance (e.g., in
cardiomiocytes; Oudit et al., 2006).
Different is the situation of iron homeostasis in the central
nervous system (CNS): although the mechanisms are still
debated and somewhat controversial, a large body of evidence
indicates that the iron control in CNS is virtually independent
of the rest of the body. Indeed, conditions of systemic iron
overload or deficiency are reported not to significantly affect
the brain (Russo et al., 2004; Moos et al., 2007). Moreover,
also the role and the contribution of transferrin-bound iron
and NTBI to iron homeostasis appear clearly different in the
two compartments. In fact, transferrin-bound iron is reported
to operate with the same mechanisms described at the systemic
level in neurons but not in glial cells. On the other hand, NTBI
is attracting more attention in light of the various mechanisms
that are potentially involved and of the possible regulation they
are subjected to during synaptic activity (see next chapter).
Based on this premise, we will focus our attention on NTBI,
its composition and the mechanisms sustaining its uptake in
brain cells.
NTBI in the Brain
Brain shows clear differences in the control of iron homeostasis
that can account for its specific physiopathological behavior.
Despite the difficulty of measuring iron concentration within
the cerebrospinal fluid (CSF) and brain interstitium, a value
much lower than in the plasma was estimated (0.25–1 µM
vs. ∼20 µM). Considering that the concentration of the
Tf produced in the brain (by the choroid plexuses and
oligodendrocytes) is more than two orders of magnitude
lower than in the plasma (i.e., ∼0.2 µM vs. ∼30 µM), Tf
is expected to be fully saturated in the CSF. Accordingly,
NTBI significantly contributes to total iron in CSF and
brain interstitium even in physiological conditions (Molina
et al., 1998; Moos and Morgan, 1998; Mizuno et al., 2005;
Hozumi et al., 2011). Moreover, the presence of a very high
concentration of ascorbate in the CSF (up to 100 times,
compared to plasma; Bradbury, 1997; Lane et al., 2010),
generates a reducing environment that increases the ratio
Fe(II)/Fe(III) in NTBI. The expression of different ferric
reductases (duodenal cytochrome B, Dcytb, and stromal cell-
derived receptor 2, SDR2) further contributes to make Fe(II)
the prominent form of iron in the NTBI (Tulpule et al.,
2010). This is particularly relevant since Fe(II) represents the
main form of iron acquirable by astrocytes, which do not
have Tf receptors, but also an important source for neurons
(Moos et al., 2007; Pelizzoni et al., 2011, 2013). However,
NTBI has not only a relevant physiological role in the CNS
but it can acquire a pathological relevance, as suggested
by growing evidence that NTBI levels increase during aging
as well as in several neurodegenerative disorders (Bradbury,
1997; Breuer et al., 2000; Crichton et al., 2011). From this
standpoint, the NTBI can be related to the onset and the
progression of neurodegenerative disorders, not necessarily
related to genetic alteration of iron homeostasis. Therefore, a
thorough characterization of the cellular pathways and of the
molecular mechanisms controlling NTBI in the brain can open
new vistas on the etiopathogenesis of many neurodegenerative
diseases.
Mechanisms of NTBI Uptake by Neurons
and Astrocytes
A number of questions are still open about the mechanisms of
NTBI entry in brain-derived cells: which are the pathways
that operate in neurons and astrocytes? Which is their
relevance in specific brain regions? Can neuronal functions
and, in particular, synaptic activity, influence NTBI uptake?
And, finally, can pathological conditions affect these
pathways?
NTBI uptake was first proposed in cortical neurons (Cheah
et al., 2006), where a role for divalent metal transporter 1
(DMT1), the main iron transporter expressed in mammalian
cells (Gunshin et al., 1997), was reported. In particular, it was
suggested that a calcium influx mediated by the glutamatergic
N-methyl-D-aspartate receptor (NMDAR) is able to promote
a positive modulation of the transporter, and thus of Fe(II)
uptake, as a consequence of its interaction with Dexras1 (a
member of the Ras family) via an adaptor protein. However no
evidence of a direct involvement of DMT1 in the iron influx
was provided; moreover, data were not obtained in physiological
conditions, since the experiments were performed at a pH of
5.5. This paper thus proposes, for the first time, a link between
synaptic activity and iron entry in neuronal cells. This general
concept also emerged in a following study from Hidalgo’s
group (Haeger et al., 2010) in which it was reported that a
brief stimulation with NMDA was sufficient to promote the
transcription of the isoform 1B/IRE(+) of DMT1 in hippocampal
neurons; however, in this paper, iron entry was not evaluated.
Of note, when DMT1-1B/IRE(+) was overexpressed in epithelial
cell lines as well as in primary neurons, it was not localized in
the recycling endosome, but in the late endosomes/lysosomes,
and it was not involved in iron uptake (Yanatori et al., 2010;
Pelizzoni et al., 2012). As an alternative, it was proposed that
the Fe(II) may enter neurons directly through Ca2+-permeable
channels and, in particular, voltage-operated calcium channels
(VOCCs) andNMDARs (Pelizzoni et al., 2011). Thismechanism,
which might regard all VOCCs but not all Ca2+-permeable
channels, involves the competition between Ca2+ and Fe(II)
for the same entry pathway (Lopin et al., 2012), a condition
also described in neuronal cell lines (Gaasch et al., 2007)
These results are in accordance with those obtained on a
model of iron-overloaded cardiomyocytes (Oudit et al., 2003),
in which the L-type VOCCs represent the main mechanisms
of Fe(II) entry and thus, of iron-induced cardiomyopathy. The
possibility that neurons from different brain areas might differ
for the mechanisms of iron entry remains open. Moreover
neurons may also acquire the competence to activate specific
pathways when the physiological conditions are altered (see
below).
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Also astrocytes show a great complexity of iron control,
particularly considering that in these cells Tf receptor
1 was reported not to be expressed in vivo (Moos and
Morgan, 2004; Jeong and David, 2006). Recent studies
have proposed that cultured astrocytes are capable of
importing both Fe(II) and Fe(III) and that in the presence
of ascorbate, to reproduce the in vivo reducing conditions,
iron accumulation is further enhanced (Lane et al., 2010;
Tulpule et al., 2010). In both papers an involvement of DMT1
was proposed, even though additional pathways were not
excluded. Overall, DMT1 has received great attention and
has conditioned our general view of iron uptake. However,
the in vivo expression of DMT1 was reported to be confined
to astrocytic perivascular endfeet (Moos and Morgan, 2004).
Other mechanisms, such as the zinc transporter Zip14, have
been proposed for NTBI uptake in astrocytes, even though
their physiological role is still to be established (Bishop et al.,
2011).
More recently it was shown that, in physiological conditions,
Fe(II) can enter the hippocampal astrocytes through the transient
receptor potential canonical (TRPC) channels, with an irrelevant
involvement of DMT1 (Pelizzoni et al., 2013). However, upon
exposure to proinflammatory cytokines and ensuing activation,
astrocytes expressed the DMT1-1A, i.e., the isoform localized
on the apical membrane of enterocytes (Hubert and Hentze,
2002). Accordingly, the de novo expression of this isoform of
DMT1 in activated astrocytes was proposed to account for their
increased capability to uptake Fe(II), but not Fe(III) (Rathore
et al., 2012; Pelizzoni et al., 2013; Urrutia et al., 2013). In light
of these results, the discrepancies on the importance of DMT1 in
astrocytic Fe(II) uptake might be ascribed to the high variability
of the culture conditions that can promote different extents of
astrocyte activation (Saura, 2007).
Effects of NTBI on Neurons and Role of
Astrocytes
We have seen that NTBI is a relevant source of iron and
that various mechanisms can control its supply to neurons
and astrocytes. This contribution is important to restore the
pool of iron-sulphur clusters and thus to meet the elevate
energy consumption caused by neuronal activity, but also to
sustain specific neuronal functions, such as neurotransmitter
synthesis. Moreover, NTBI can contribute to the ‘‘oxidative
tone’’ which is important for both basal synaptic transmission
and long-term potentiation (LTP; Muñoz et al., 2011). In
particular, it was reported that the iron-mediated reactive oxygen
species (ROS) production is required in hippocampal neurons to
promote calcium release from ryanodine receptor after NMDA
stimulation, an essential event for a sustained LTP. Therefore,
a direct coupling between synaptic activity and iron entry can
properly address these requirements. However, this is a double-
edged sword in that iron entry, if not properly controlled,
represents a harmful condition, because of the capability of
Fe(II) to catalyze the so-called Fenton reaction, which occurs
primarily at the mitochondrial level with production of the
highly toxic hydroxyl radical (Halliwell, 2006). Accordingly, an
increase in NTBI or a potentiation of the import mechanisms
can cause high detrimental effects in neurons. A link between
elevation of iron levels and neurodegenerative processes has
been proposed for aging as well as in several pathological
conditions (Altamura and Muckenthaler, 2009; Crichton et al.,
2011). The toxic effects of iron accumulation in brain can be
particularly harmful when Fe(II) enters the neurons through
Ca2+-permeable channels since it is not controlled by the
same intracellular iron level as it occurs for the Tf-mediated
pathway and, possibly, also for DMT1 (Hentze et al., 2010).
Moreover, the concomitant influx of iron and Ca2+ can
greatly contribute to excitotoxicity in glutamatergic neurons
(Dixon et al., 2012; Chen et al., 2013). More in general,
conditions of increased synaptic activity, in the presence of
elevated iron, can cause iron overload and concur to the
development of cytotoxic effects (Pelizzoni et al., 2008), as it
was suggested to occur in Alzheimer disease (Altamura and
Muckenthaler, 2009). Also a potentiation of the mechanisms
of iron import can lead up to this dangerous chain of
effects. Indeed, an enhancement of DMT1 expression was
reported after induction of excitotoxicity (Huang et al., 2006)
or hypoxia (Wang et al., 2010) as well as in animal and cellular
models of Parkinson disease (Salazar et al., 2008; Du et al.,
2009).
This general framework can be further exacerbated in
conditions of acute brain injuries and inflammation, which
accompany several neurodegenerative disorders, since local
acidification favors the reduction of Fe(III) to Fe(II) and
potentiates the H+/metal-ion cotransport activity of DMT1
(Mackenzie et al., 2007).
Within this context, astrocytes also play an important role.
They were described as participating in brain iron homeostasis
under conditions of iron deprivation, with soluble ceruplasmin,
released by the same astrocytes, supporting iron uptake in
neurons, even though the mechanisms were not elucidated (Ke
et al., 2006). More recently, it has been proposed that they
participate in the synaptic activity also by buffering iron. Indeed,
astrocytes are endowed with high detoxifying defences that
make them more resistant than neurons to oxidative insults
(Pelizzoni et al., 2011). Under physiological conditions, and
even more in the presence of extracellular iron accumulation,
these glial cells might buffer perisynaptic iron by uptaking it
via TRPC, thereby actively contributing to lowering synaptic
iron load. Of note, the activity of members of the TRPC
family is enhanced by decreasing the extracellular pH (Semtner
et al., 2007) to values comparable to those observed when
exocytosis of the synaptic vesicle is evoked (Palmer et al.,
2003).
Overall, it is temping to envision a model in which an
increase in synaptic activity favors iron overload in neurons,
a condition that is counteracted by the active iron buffering
of astrocytes. This protective role is expected to be enhanced
during inflammatory conditions when local acidification and
astrocyte activation (Xiong et al., 2008), with de novo expression
of the DMT1, further enhance iron buffering. This condition
has been recently reported in an experimental model of multiple
sclerosis, where a significant increase in DMT1 expression was
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FIGURE 1 | Scheme of the main mechanisms of Fe(II) entry in neurons and astrocytes. Notice that µglia indicates a microglia cell. See text for further details
and explanations.
observed in astrocytes around the lesions, making them more
efficient in recycling iron from the sites of lesions (Zarruk
et al., 2015). Of note, inflammatory conditions can cause
astrocyte activation with ensuing higher protection against iron-
mediated oxidative stress (Macco et al., 2013). Conversely, the
expression of DMT1 in neurons, as reported in some pathological
conditions, might favor iron overload and represent a concause
in the neurodegenerative processes.
Conclusions
Data in the literature propose multiple mechanisms for iron
entry in both neurons and astrocytes (summarized in Figure 1)
and draw the attention to the role of the neuronal activity
on iron influx. In the excitatory synapses of hippocampal
neurons, iron uptake depends on the direct stimulation of
NMDA receptors and indirect activation of VOCCs (by synaptic
activation, back propagating action potentials or depolarization
from adjacent synapses). DMT1 can have a physiological role
in other brain areas, still showing a dependence on synaptic
activity, or can be expressed in some pathological conditions
(e.g., Parkinson disease). Within this general framework, iron
uptake strongly depends on its availability that can vary with
age and in some neurodegenerative diseases (Bradbury, 1997;
Molina et al., 1998). In this respect, astrocytes, closely associated
to neurons, operate to buffer the excess of extracellular iron. This
is important under physiological conditions but, particularly,
in pathological conditions when this competence is reinforced
by the expression of additional mechanisms of iron uptake.
Overall, this complex interplay, including the functional coupling
of astrocytes through gap junctions, may help in buffering
iron and in protecting neurons during neuroinflammation and
neurodegenerative processes.
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